AVI BioPharma, Inc. (AVII), a developer of RNA-based drugs, today announced the impending strategic move of its corporate headquarters and much of its leadership team to the greater Seattle area. The company plans to build upon and broaden its clinical development and drug discovery skill base by drawing upon the region's scientific expertise. The move will enable AVI to streamline its corporate operations and upgrade its capability to add new drug candidates to its pipeline in neuromuscular, immunological and viral diseases. The move is from Corvallis, OR.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment